Danish biotech Genmab has appointed Martine van Vugt to the role of chief strategy officer, overseeing corporate strategy, licensing and business development, a 28 March 2023
Antisense oligonucleotide (ASO) firm Secarna Pharmaceuticals has partnered with fellow German company SciNeuro Pharmaceuticals to take aim at central nervous sy 28 March 2023
Canada’s AbCellera and British firm RQ Bio will work together to identify clinical candidates for up to three infectious disease targets, under the terms of a n 22 March 2023
A new gene editing company, Seamless Therapeutics, has launched in Germany with $12.5 million in seed financing from investors including Wellington Partners and 16 March 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.